Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Bio CMO Market: Size, Trends & Forecasts (2018-2022) with Lonza Group, Boehringer Ingelheim, Samsung Biologics and Wuxi Biologics Dominating - Research and Markets

Research and Markets
Posted on: 04 Jan 18

The "Global Bio CMO Market: Size, Trends & Forecasts (2018-2022)" report has been added to Research and Markets' offering.

Global Bio CMO Market: Size, Trends & Forecasts (2018-2022) provides analysis of the global bio CMO market, with detailed analysis of market size and growth, penetration, market share and economic impact of the industry. The report also provides the analysis of the global biologics market by value, by top selling products, etc.

Growth of the overall global bio CMO market has been forecasted for the years 2017-2022, taking into consideration the previous growth pattern, the growth drivers and the current and future trends.

The global bio CMO market is expected to increase at a significant growth rate during the forecasted period (2017-2022). The global bio CMO market is supported by various growth drivers, such as increase in pharmaceutical industry, growth in use of biosimilars, potential biologics blockbusters, introduction of targeted therapins, greater outsourcing demand from global pharmas, etc. Yet, the market faces certain challenges, such as risk associated with CMOs, presence of in-house manufacturing facilities of big pharma companies, productivity issues with mammalian cell system, etc.

Lonza Group, Boehringer Ingelheim, Samsung Biologics and Wuxi Biologics are key companies in the global bio CMO market.

The world's largest pharmaceutical firms are located in the North America, Europe and Japan. On the basis of technological platform, pharmaceutical drugs can be divided into small molecule or conventional drugs and large molecule or biologic drugs.

Biologics are made through biological processes and are generally injected. Biologics comprises of vaccines, blood or blood components, somatic cells, gene therapy, etc. Biologics are categorized into first-or second generation, depending on development period and cell line. Biosimilars are the biological that are similar, but not identical to the original product.

On the basis of production technology, bio CMOs can be divided into mammalian cell system and microbial system.

Key Topics Covered:

1. Executive Summary

2. Introduction

3. Global Market Analysis

4. Competitive Landscape

5. Company Profiles

  • Boehringer Ingelheim
  • Lonza Group
  • Samsung Biologics
  • Wuxi Biologics

For more information about this report visit

View source version on

Business Wire

Last updated on: 04/01/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.